Calcium channel blockers: Resolving the controversy

Norman M Kaplan

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Ongoing controversies about the use of calcium channel blockers (CCBs) have caused major agitations in patients and physicians' management of hypertension. The controversy about short-acting nifedipine has highlighted the inappropriate use of this agent for indications that were never approved. However, the other elements of the controversy have no scientific basis and do not in any way incriminate the appropriate use of long-acting CCBs. Prospective, controlled studies are now available documenting the safety of long-acting CCBs and additional large-scale trials are in progress.

Original languageEnglish (US)
Pages (from-to)567-572
Number of pages6
JournalDrugs of Today
Issue number7
StatePublished - 1996

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Calcium channel blockers: Resolving the controversy'. Together they form a unique fingerprint.

Cite this